Quantcast

Latest Aripiprazole Stories

2014-09-03 12:28:27

Facing Higher Costs, MCOs Will Push for Lower-Cost Treatments, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 3, 2014 /PRNewswire/ -- Decision Resources Group finds that surveyed managed care organizations (MCOs), psychiatrists and primary care physicians (PCPs) anticipate a significant increase in demand for drugs treating major depression, bipolar disorder and schizophrenia, owing to the expansion of Medicaid (in 24 states) and the availability of affordable...

2014-08-27 23:05:59

Making medications affordable can help lower the mortality rate of mental illnesses like depression or bi-polar disorder. Houston, TX (PRWEB) August 27, 2014 Many patients believe mental illness is not life threatening. The reality is that depression has a mortality rate of about 15%. The suicide rate for those with bi-polar disorder is slightly less, though it's offset by an alarming homicide rate (including attempted homicide) of roughly 7%. In order to properly treat and manage...

2014-08-13 12:28:00

Despite Expanding Generic Availability, Opportunity Remains for New Therapies, Particularly for Treatment-Resistant Depression, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug. 13, 2014 /PRNewswire/ -- Decision Resources Group finds that in the unipolar depression* market, the expanding use of two recently approved therapies--Lundbeck/Takeda Pharmaceutical's Brintellix (vortioxetine), Actavis (formerly Forest Laboratories)/Pierre Fabre's Fetzima (levomilnacipran...

2014-06-23 12:29:42

Data Highlight Physician and Payer Receptivity to Emerging Agents for Treatment-Resistant Depression, According to Findings from Decision Resources Group BURLINGTON, Mass., June 23, 2014 /PRNewswire/ -- Decision Resources Group finds that surveyed U.S. psychiatrists are receptive to novel adjunctive therapies to antidepressants for treatment-resistant depression (TRD) and would prescribe Otsuka/Lundbeck's emerging atypical antipsychotic brexpiprazole to a mean 12 percent of their drug-treated...

2014-05-05 08:28:42

MONTREAL, May 5, 2014 /CNW/ - Canadians living with schizophrenia now have a new option to help treat their disease. Otsuka Canada Pharmaceutical Inc. and Lundbeck Canada Inc. announce today that ABILIFY MAINTENA(TM) (aripiprazole for prolonged release injectable suspension), indicated for the maintenance treatment of schizophrenia in stabilized adult patients, is now commercially available for use in Canada. ABILIFY MAINTENA(TM) is the first product in Canada from the global...

2014-03-28 12:26:07

DUBLIN, March 28, 2014 /PRNewswire/ -- Dublin - Research and Markets ( http://www.researchandmarkets.com/research/cw7xqm/investigation) has announced the addition of the "Investigation Report on China's Aripiprazole Market, 2009-2018" [http://www.researchandmarkets.com/research/cw7xqm/investigation ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Schizophrenia is a common mental disorder. Data shows that mental illness has...

2014-03-17 12:27:36

Ameritox offers medical and behavioral health professionals additional information in helping to assess medication non-adherence by those diagnosed with serious mental health issues BALTIMORE, March 17, 2014 /PRNewswire/ -- Ameritox(SM), the nation's leader in medication monitoring solutions, introduced a new method to assist physicians in assessing medication non-adherence for patients with serious mental illness prescribed the antipsychotic drug Abilify, the top-selling medication...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related